

CLAIMS OF THE APPLICATION

1-17. (Canceled)

18. (New) A pharmaceutical composition comprising:

- a) a tablet layer comprising an antihistaminic drug, a cellulose derivative, a polyol, a starch derivative, and a disintegrant; and
- b) a tablet layer comprising a decongestant drug and a sustained release compound.

19. (New) The pharmaceutical composition of claim 18, wherein an antihistaminic drug comprises crystalline Form X of fexofenadine hydrochloride.

20. (New) The pharmaceutical composition of claim 18, wherein a cellulose derivative comprises powdered cellulose, microcrystalline cellulose, or a mixture thereof.

21. (New) The pharmaceutical composition of claim 18, wherein a polyol comprises mannitol, xylitol, or a mixture thereof.

22. (New) The pharmaceutical composition of claim 18, wherein a starch derivative comprises corn starch, potato starch, starch 155, or a mixture of any two or more thereof.

23. (New) The pharmaceutical composition of claim 18, wherein a disintegrant comprises sodium starch glycolate, sodium carboxymethylcellulose, crosslinked polyvinylpyrrolidone, croscarmellose sodium, or a mixture of any two or more thereof.

24. (New) The pharmaceutical composition of claim 18, wherein a decongestant drug comprises pseudoephedrine, phenylephrine, phenylpropanolamine, a pharmaceutically acceptable salt of any of the foregoing, or a mixture of any two or more thereof.

25. (New) The pharmaceutical composition of claim 18, wherein a sustained release compound comprises: a mixture comprising polyvinyl acetate and povidone; sodium alginate; xanthan gum; carbopol; chitosan; ethyl cellulose; a cellulose ether; a methacrylic polymer; or a mixture of any two or more thereof.

26. (New) The pharmaceutical composition of claim 18, wherein an antihistaminic drug comprises crystalline form X of fexofenadine hydrochloride and a decongestant drug comprises pseudoephedrine or a salt thereof.

27. (New) A pharmaceutical composition comprising:

a) a tablet layer comprising an antihistaminic drug, cellulose, mannitol, starch, and croscarmellose sodium; and

b) a tablet layer comprising a decongestant drug and a mixture of polyvinyl acetate and povidone.

28. (New) The pharmaceutical composition of claim 27, wherein an antihistaminic drug comprises crystalline form X of fexofenadine hydrochloride.

29. (New) The pharmaceutical composition of claim 27, wherein a decongestant drug comprises a salt of pseudoephedrine.

30. (New) The pharmaceutical composition of claim 27, wherein tablet layer a) comprises about 20 to about 45 percent by weight cellulose.

31. (New) The pharmaceutical composition of claim 27, wherein tablet layer a) comprises about 10 to about 30 percent by weight mannitol.

32. (New) The pharmaceutical composition of claim 27, wherein tablet layer a) comprises about 5 to about 25 percent by weight starch.

33. (New) The pharmaceutical composition of claim 27, wherein tablet layer a) comprises about 4 to about 15 percent by weight croscarmellose sodium.

34. (New) The pharmaceutical composition of claim 27, wherein tablet layer b) comprises about 40 to about 80 percent by weight of a mixture of polyvinyl acetate and povidone.

35. (New) The pharmaceutical composition of claim 27, wherein tablet layer b) comprises about 40 to about 80 percent by weight of a mixture comprising about 80 percent polyvinyl acetate and about 19 percent povidone.

36. (New) The pharmaceutical composition of claim 27, wherein tablet layer b) is formed by compressing granules comprising a decongestant drug and a mixture of polyvinyl acetate and povidone, about 5-15 percent of the granules being retained on an 80 mesh sieve, about 10-25 percent of the granules being retained on a 100 mesh sieve, and about 80-95 percent of the granules being retained on a 200 mesh sieve.

37. (New) A pharmaceutical composition comprising:

a) a tablet layer comprising crystalline form X of fexofenadine hydrochloride, about 20 to about 45 percent by weight cellulose, about 10 to about 30 percent by weight mannitol, about 5 to about 25 percent by weight starch, and about 5 to about 25 percent by weight starch; and

b) a tablet layer comprising a salt of pseudoephedrine and about 40 to about 80 percent by weight of a mixture comprising about 80 percent polyvinyl acetate and about 19 percent povidone.